<?xml version="1.0" encoding="UTF-8"?>
<fig id="f1-1040797" position="float">
 <label>Figure 1.</label>
 <caption>
  <p>Progression-free survival (PFS) after first-line therapy. PFS according to (A) treatment and (B) fluorescence 
   <italic>in situ</italic> hybridization (FISH) cytogenetic status. F/FC: fludarabine/fludarabine in combination with cyclophosphamide; CLB+/-R: chlorambucil and rituximab; FCR: fludarabine in combination with cyclophosphamide and rituximab; B/BR: bendamustine/bendamustin and rituximab; ALEM: alemtuzumab; CHOP/CVP+/-R: cyclophosphamide+hydroxydaunorubicin+vincristine+prednisone/cyclophosphamid+vincristine+prednisone+rituximab.
  </p>
 </caption>
 <graphic xlink:href="104797.fig1" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
